Barclays
CRL icon

Barclays’s Charles River Laboratories CRL Stock Holding History

Barclays’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$980K – 5239
2023
Q3 		$980K Buy
+5,000
New +$1.03M ﹤0.01% 2355
2014
Q3 		– Sell
-100
Closed -$5K – 7670
2014
Q2 		$5K Hold
100
– – ﹤0.01% 7107
2014
Q1 		$6K Buy
+100
New +$5.83K ﹤0.01% 7128
2013
Q4 		– Sell
-50,000
Closed -$2.3M – 7545
2013
Q3 		$2.3M Buy
+50,000
New +$2.29M ﹤0.01% 2413

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barclays's CRL Position: Q1 2026 in Review

Barclays increased its Charles River Laboratories (CRL) stake by 297% in Q1 2026, buying an estimated $32.6M and bringing the position to 234,936 shares worth $40.5M. The position accounts for 0.01% of the portfolio, ranked #801.

Barclays first reported a position in CRL in Q2 2013 and has held it in 50 quarters since. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Barclays held 234,936 shares of Charles River Laboratories worth $40.5M as of Q1 2026.
  • Barclays bought 175,802 Charles River Laboratories shares in Q1 2026, an estimated $32.6M.
  • Charles River Laboratories made up 0.01% of Barclays's portfolio in Q1 2026, its #801 holding.
  • Barclays first reported a position in Charles River Laboratories in Q2 2013 and has held it in 50 quarters since.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.